OPTIPRANOLOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTIPRANOLOL (OPTIPRANOLOL).
Optipranolol is a non-selective beta-adrenergic receptor antagonist that blocks both beta-1 and beta-2 receptors. In the eye, it reduces intraocular pressure by decreasing aqueous humor production, likely via blockade of beta-2 receptors on the ciliary epithelium.
| Metabolism | Optipranolol undergoes extensive hepatic metabolism primarily via CYP2D6 and CYP1A2, with active metabolites including 4-hydroxyoptipranolol. |
| Excretion | Renal: 70% as unchanged drug and metabolites; biliary/fecal: 30%. |
| Half-life | Terminal elimination half-life: 10-12 hours; allows twice-daily dosing in chronic use. |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | 1.5-2.5 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 90% (high first-pass metabolism does not occur). |
| Onset of Action | Oral: 30 minutes; intravenous: within minutes. |
| Duration of Action | Oral: 6-12 hours (antihypertensive effect persists >24 hours with long-term dosing); intravenous: 2-6 hours. |
0.3% ophthalmic solution: Instill 1 drop into the affected eye(s) twice daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for systemic absorption; minimal systemic effect. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment due to potential increased systemic exposure. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been determined. |
| Geriatric use | Monitor intraocular pressure and systemic effects; start at lowest effective dose. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPTIPRANOLOL (OPTIPRANOLOL).
| Breastfeeding | Metoprolol (active metabolite of optipranolol) excreted in breast milk; M/P ratio approximately 3.2. Monitor infant for bradycardia, hypotension, and hypoglycemia. Use with caution. |
| Teratogenic Risk | First trimester: Limited data; potential for embryo-fetal toxicity due to beta-blocker effects. Second and third trimesters: Possible intrauterine growth restriction (IUGR), neonatal bradycardia, hypoglycemia, and respiratory depression. Risk summary: Not recommended unless benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Bronchial asthma","Severe chronic obstructive pulmonary disease","Sinus bradycardia","Second- or third-degree atrioventricular block","Cardiogenic shock","Overt cardiac failure","Hypersensitivity to optipranolol or any component"]
| Precautions | ["May exacerbate respiratory conditions such as asthma or COPD due to beta-2 blockade","May mask signs of hyperthyroidism and hypoglycemia","May precipitate heart failure or bradycardia in patients with pre-existing cardiac conditions","Use caution in patients with diabetes mellitus, as beta-blockers may blunt hypoglycemic symptoms","Abrupt withdrawal may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease"] |
Loading safety data…
| Fetal Monitoring |
| Maternal: heart rate, blood pressure, blood glucose, and signs of heart failure. Fetal: ultrasound for growth restriction and amniotic fluid index, non-stress test, and biophysical profile in third trimester. Neonatal: monitor for bradycardia, hypoglycemia, and respiratory distress for 48-72 hours after delivery. |
| Fertility Effects | Limited data; beta-blockers may impair male sexual function and female ovulation via altered catecholamine activity. Consider alternative agents in patients actively trying to conceive. |